Drug Trial Radar · NCT06270433
Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder
Last checked: Nov 20, 2026Latest source record: Apr 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
80
Planned (sponsor's estimate)
Start
Feb 19, 2024
Primary completion
Dec 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Jiangsu Province Nanjing Brain HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 21, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate efficacy and safety of toludesvenlafaxine hydrochloride sustained-release tablets in the treatment of anhedonia in patients with major depression disorder compared to desvenlafaxine succinate sustained-release tablets, to provide evidence-based basis for clinical rational drug use.
Conditions
- Anhedonia
Interventions
Toludesvenlafaxine hydrochloride sustained-release tabletsDrug
80 mg or 120 mg or 160 mg orally once daily dosing for 8 weeks
Desvenlafaxine succinate sustained-release tabletsDrug
50 mg orally once daily dosing for 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Snaith-Hamilton Pleasure Scale (SHAPS) Total ScoreTime frame: Baseline and the end of week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nanjing Brian Hospital
Nanjing, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.